시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 인간 상피 성장 인자 시장 보고서(2025년)
Human Epidermal Growth Factor Global Market Report 2025
상품코드 : 1769617
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,226,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,000,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,773,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

인간 상피 성장 인자 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 예측 기간 동안의 성장은 재생 의학 및 상처 치유 응용 분야의 수요 증가, 만성 피부 질환 및 부상의 유병률 증가, hEGF를 함유한 노화 방지 및 스킨케어 제품에 대한 인식 제고, 생명 공학 연구 및 개발에 대한 투자 확대, 맞춤형 의약품 및 표적 치료법의 채택 증가에 기인할 수 있습니다. 이 기간의 주요 동향으로는 재조합 DNA 기술의 발전, hEGF의 안정성과 효능을 향상시키는 단백질 공학의 발전, 나노 기술의 통합, 생물 공정 기술의 혁신, 세포 배양 기술의 발전 등이 있습니다.

맞춤형 의약품의 채택이 증가함에 따라 인간 상피 성장 인자 시장의 성장이 더욱 촉진될 것으로 예상됩니다. 맞춤형 의약품은 개인의 유전적 특성, 생활 방식 및 환경에 따라 의료 치료를 맞춤화하여 보다 정확하고 효과적인 치료를 제공하는 의료 접근 방식입니다. 맞춤형 의약품의 부상은 맞춤형 치료를 위해 개인의 유전적 특성을 보다 빠르고 저렴하며 정확하게 파악할 수 있는 유전체 기술의 발전에 의해 촉진되고 있습니다. HER2는 의사가 HER2 단백질 과발현에 따라 종양을 분류할 수 있도록 지원하여, 치료 결과를 개선하고 불필요한 부작용을 최소화하는 표적 치료법을 선택하는 데 도움을 주어 맞춤형 의약품을 지원합니다. 예를 들어, 미국에 본사를 둔 전문 회원 조직인 Personalized Medicine Coalition은 2022년에 12개의 새로운 맞춤형 의약품이 승인되어 전체 신규 승인 치료법의 약 34%를 차지하며, 이는 전년도에 비해 크게 증가한 수치라고 보고했습니다. 결과적으로 맞춤형 의약품의 사용이 증가하면서 인간 상피 성장 인자 시장의 성장이 가속화되고 있습니다.

임상 시험의 수가 증가함에 따라 향후 인간 표피 성장 인자 시장의 성장이 촉진될 것으로 예상됩니다. 임상 시험은 의학적 치료 또는 중재의 안전성, 유효성 및 부작용을 평가하기 위해 인간을 대상으로 하는 연구입니다. 임상 시험의 증가는 안전성과 효능에 대한 철저한 테스트가 필요한 개인 맞춤형 및 혁신적인 치료법에 대한 수요 증가에 의해 촉진되고 있습니다. 인간 상피 성장 인자(hEGF)는 세포 성장과 조직 복구를 촉진하여 상처 치유, 피부 재생 및 관련 질환에 대한 치료법 평가를 용이하게 함으로써 임상 시험을 지원합니다. 예를 들어, 2023년 11월 런던에 본사를 두고 있는 영국 제약 산업 협회(Association of the British Pharmaceutical Industry)는 영국에서 산업용 임상 시험의 연간 참가자 수가 2021-22년 3만 6,722명에서 2022-23년 4만 2,088명으로 15% 증가했다고 보고했습니다. 따라서 임상 시험의 증가는 인간 상피 성장 인자 시장의 확장을 촉진하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

HBR
영문 목차

영문목차

Human epidermal growth factor (EGF) is a protein that promotes cell growth, proliferation, and differentiation by binding to the epidermal growth factor receptor (EGFR). It aids in accelerating wound healing by stimulating the migration and proliferation of skin cells like keratinocytes and fibroblasts, which are crucial for closing wounds and rebuilding tissue.

The main types of human epidermal growth factor products include recombinant human epidermal growth factor and natural human epidermal growth factor. Recombinant human epidermal growth factor (rhEGF) is a bioengineered protein created to stimulate cell growth and support tissue repair. It is available in various forms, such as injectable, topical, and oral. These products are distributed through multiple channels including direct sales, online pharmacies, retail pharmacies, hospital pharmacies, and specialty clinics. Key application areas cover dermatology, oncology, ophthalmology, wound healing, and cosmetic procedures. They are utilized by a range of end-users including hospitals, clinics, research institutes, and other healthcare facilities.

The human epidermal growth factor market research report is one of a series of new reports from The Business Research Company that provides human epidermal growth factor market statistics, including the human epidermal growth factor industry's global market size, regional shares, competitors with the human epidermal growth factor market share, detailed human epidermal growth factor market segments, market trends and opportunities, and any further data you may need to thrive in the human epidermal growth factor market. This human epidermal growth factor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human epidermal growth factor market size has grown strongly in recent years. It will grow from $2.18 billion in 2024 to $2.39 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historic period can be attributed to the expanding geriatric population susceptible to skin-related disorders, increased government support and funding for biopharmaceutical innovations, a rising prevalence of diabetes resulting in more chronic wound cases, enhanced collaborations between pharmaceutical companies and research institutes, and a growing consumer preference for non-invasive skincare solutions.

The human epidermal growth factor market size is expected to see strong growth in the next few years. It will grow to $3.37 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth during the forecast period can be attributed to the rising demand for regenerative medicine and wound healing applications, increasing prevalence of chronic skin conditions and injuries, growing awareness of anti-aging and skincare products containing hEGF, expanding investment in biotechnology research and development, and the increasing adoption of personalized medicine and targeted therapies. Key trends in this period include advancements in recombinant DNA technology, developments in protein engineering that enhance hEGF stability and efficacy, integration of nanotechnology, innovations in bioprocessing techniques, and progress in cell culture technology.

The increasing adoption of personalized medicine is expected to drive the growth of the human epidermal growth factor market moving forward. Personalized medicine is a healthcare approach that customizes medical treatment based on an individual's genetic profile, lifestyle, and environment to provide more precise and effective care. The rise in personalized medicine is fueled by advances in genomic technologies, which allow faster, more affordable, and more accurate identification of individual genetic profiles for tailored treatments. HER2 supports personalized medicine by enabling physicians to classify tumors according to HER2 protein overexpression, helping select targeted therapies that improve outcomes and minimize unnecessary side effects. For example, the Personalized Medicine Coalition, a US-based professional membership organization, reported that in 2022, 12 new personalized medicines were approved, representing about 34% of all newly approved therapies-a significant increase from previous years. Consequently, the growing use of personalized medicine is propelling the growth of the human epidermal growth factor market.

The rising number of clinical trials is expected to drive the growth of the human epidermal growth factor market in the future. Clinical trials are research studies involving human participants to assess the safety, effectiveness, and side effects of medical treatments or interventions. The increase in clinical trials is fueled by the growing demand for personalized and innovative therapies that require thorough testing for safety and efficacy. Human epidermal growth factor (hEGF) supports clinical trials by promoting cell growth and tissue repair, facilitating the evaluation of treatments for wound healing, skin regeneration, and related conditions. For example, in November 2023, the Association of the British Pharmaceutical Industry, a London-based trade association, reported a 15% increase in annual recruitment for industry clinical trials in the UK, rising from 36,722 participants in 2021-22 to 42,088 in 2022-23. Thus, the growth in clinical trials is propelling the expansion of the human epidermal growth factor market.

Leading companies in the human epidermal growth factor market are focusing on technological innovations such as AI-powered immunohistochemistry (IHC) scoring solutions to enhance the accuracy, speed, and consistency of biomarker detection and cancer diagnostics. An AI-powered IHC scoring solution uses artificial intelligence algorithms to automatically analyze and quantify protein expression in tissue samples stained via IHC, improving precision, reproducibility, and efficiency in diagnostic pathology. For example, in September 2023, Ibex Medical Analytics, an Israel-based company, introduced Ibex Breast HER2. This technology improves the precision and consistency of HER2 biomarker scoring in breast cancer, particularly in difficult HER2-low cases, enabling optimized treatment plans and better patient outcomes. Its key benefits include highly accurate, reproducible, and efficient HER2 IHC scoring, assisting pathologists in making confident, objective decisions for selecting targeted therapies.

Major players in the human epidermal growth factor market are Pfizer Inc., Johnson & Johnson Services Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, AstraZeneca plc, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., Lonza Group AG, STEMCELL Technologies, Abcam plc., BioLegend Inc., Bharat Biotech International Limited, RayBiotech Inc., Enzo Life Sciences Inc., Neocutis S.A, Proteintech Group Inc., Creative BioMart Co. Ltd., Abbkine Scientific Co. Ltd.

North America was the largest region in the human epidermal growth factor market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human epidermal growth factor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human epidermal growth factor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human epidermal growth factor market consists of sales of skincare serums and creams, wound-healing gels and ointments, and hair growth treatments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Epidermal Growth Factor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human epidermal growth factor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for human epidermal growth factor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human epidermal growth factor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Human Epidermal Growth Factor Market Characteristics

3. Human Epidermal Growth Factor Market Trends And Strategies

4. Human Epidermal Growth Factor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Epidermal Growth Factor Growth Analysis And Strategic Analysis Framework

6. Human Epidermal Growth Factor Market Segmentation

7. Human Epidermal Growth Factor Market Regional And Country Analysis

8. Asia-Pacific Human Epidermal Growth Factor Market

9. China Human Epidermal Growth Factor Market

10. India Human Epidermal Growth Factor Market

11. Japan Human Epidermal Growth Factor Market

12. Australia Human Epidermal Growth Factor Market

13. Indonesia Human Epidermal Growth Factor Market

14. South Korea Human Epidermal Growth Factor Market

15. Western Europe Human Epidermal Growth Factor Market

16. UK Human Epidermal Growth Factor Market

17. Germany Human Epidermal Growth Factor Market

18. France Human Epidermal Growth Factor Market

19. Italy Human Epidermal Growth Factor Market

20. Spain Human Epidermal Growth Factor Market

21. Eastern Europe Human Epidermal Growth Factor Market

22. Russia Human Epidermal Growth Factor Market

23. North America Human Epidermal Growth Factor Market

24. USA Human Epidermal Growth Factor Market

25. Canada Human Epidermal Growth Factor Market

26. South America Human Epidermal Growth Factor Market

27. Brazil Human Epidermal Growth Factor Market

28. Middle East Human Epidermal Growth Factor Market

29. Africa Human Epidermal Growth Factor Market

30. Human Epidermal Growth Factor Market Competitive Landscape And Company Profiles

31. Human Epidermal Growth Factor Market Other Major And Innovative Companies

32. Global Human Epidermal Growth Factor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Epidermal Growth Factor Market

34. Recent Developments In The Human Epidermal Growth Factor Market

35. Human Epidermal Growth Factor Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기